Genome editing company MilliporeSigma said the Australian Patent Office granted it patent rights relating to the use of CRISPR in a genomic integration method for eukaryotic cells.
The patent is the first that MilliporeSigma has received for CRISPR technology.
The patent covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells — such as mammalian and plant cells — and insertion of an external or donor DNA sequence into those cells using CRISPR.
“MilliporeSigma has developed an incredible tool to give scientists the ability to find new treatments and cures for conditions for which there are limited options, including cancer, rare diseases and chronic conditions, such as diabetes,” said Udit Batra, CEO, MilliporeSigma.
“This patent decision recognizes our expertise in CRISPR technology — a body of knowledge that we are committed to grow.”
MilliporeSigma has patent filings for its insertion CRISPR method in the United States, Brazil, Canada, China, Europe, India, Israel, Japan, Singapore and South Korea.
MilliporeSigma said CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, was advancing treatment options for some of the toughest medical conditions faced today.
It said CRISPR applications were far-ranging — from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.